GlobeNewswire Inc.··NaInventiva to Report 2025 Results as MASH Drug Candidate Advances
Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results
lanifibranor
4 articlesGlobeNewswire Inc.··NaGlobeNewswire Inc.··NaInventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3
Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.··InventivaInventiva Reports €99.3M Cash Position Following $172.5M Capital Raise
Inventiva raises $172.5M, boosting cash position to €99.3M and extending runway through mid-2027 to fund MASH therapy development.
IVAcash positionfinancing
GlobeNewswire Inc.··NaInventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway
Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical